Phase I Study of CAR-T Cells with PD-1 and TCR Disruption in Mesothelin-Positive Solid Tumors

The authors generated PD-1 and T cell receptor deficient mesothelin-specific CAR-T cells using CRISPR-Cas9 technology and evaluated them in a dose-escalation study.